Professor Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 4 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle,and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies. In addition he is the Clinical Director for Cancer for the Yorkshire, Hull and North East England Genomic Medicine Service and led the NHSE pilot assessing the cost-effectiveness of cfDNA in patients presenting with advanced lung cancer. He is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University Cancer.